Freeport-McMoRan Facing Reduced Output in Indonesia Mine, Morgan Stanley Says

-- Freeport-McMoRan (FCX) is facing a slower production ramp-up and a temporary increase in costs at its Grasberg Block Cave mine in Indonesia, which may weigh on the company's shares, Morgan Stanley said in a note Friday.

The investment bank noted, however, that the long-term prospects of the Indonesian mine remain unchanged.

Morgan Stanley updated its estimates for the company following its Q1 results and now expects EBITDA of $2.44 billion in Q2, up 11% versus the previous forecast, $11.37 billion in 2026, down 10%, and $14.69 billion in 2027, down 13%, as well as $16.04 billion in 2028, a decrease of 3%.

The investment firm said its EBITDA forecasts for 2026 to 2028 are 14% to 20% below the Visible Alpha consensus estimates.

Morgan Stanley downgraded Freeport-McMoRan to equal-weight from overweight and cut the price target to $66 from $70.

Freeport-McMoRan shares were up 0.6% in Friday trading.

Price: $61.67, Change: $+0.19, Percent Change: +0.31%

Lucid Diagnostics Completes $18 Million Direct Offering of Shares

Lucid Diagnostics (LUCD) said Friday that is has completed its underwritten direct offering of 18 million shares at $1 per share.The company said the offering was anchored by a $15 million investment from a "fundamental" institutional investor with support from a large existing shareholder.Lucid said it plans to use the net proceeds for working capital and general corporate purposes.Price: $1.09, Change: $-0.01, Percent Change: -0.46%

$LUCD

Dover Sees Strong Bookings Growth, Demand Momentum, RBC Capital Markets Says

Dover (DOV) reported a modest Q1 operating beat, with 24% bookings growth and a 1.20x book-to-bill ratio pointing to demand momentum, RBC Capital Markets said in a Thursday note.The firm said bookings strength was broad-based, with all segments posting book-to-bill above 1.10x.RBC highlighted strength in clean energy components, fluid transport, retail fueling, refrigerated door cases, heat exchangers and CO2 refrigeration systems.The firm also said bookings strength suggests upside to Dover's 3% to 5% organic growth guidance. Dover reaffirmed its 2026 adjusted earnings per share guidance of $10.45 to $10.65, and revenue growth outlook of 5% to 7%.RBC raised its price target to $252 from $225, and maintained its sector perform rating on Dover.Price: $229.96, Change: $+1.81, Percent Change: +0.79%

$DOV

Pharvaris Insider Sold Shares Worth $441,726, According to a Recent SEC Filing

Anne Lesage, Chief Early Development Officer, on April 22, 2026, sold 14,700 shares in Pharvaris (PHVS) for $441,726. Following the Form 4 filing with the SEC, Lesage has control over a total of 213,319 common shares of the company, with 56,450 shares held directly and 156,869 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526176222/xslF345X05/ownership.xmlPrice: $28.49, Change: $+1.20, Percent Change: +4.40%

$PHVS

Related Articles

Lucid Diagnostics Completes $18 Million Direct Offering of Shares

Dover Sees Strong Bookings Growth, Demand Momentum, RBC Capital Markets Says

Pharvaris Insider Sold Shares Worth $441,726, According to a Recent SEC Filing